Stroke prevention in atrial fibrillation: Warfarin faces its challengers

Current Cardiology Reports

Volumn 7, Issue 1, 2005, Pages 16-22

  Blackshear, Joseph L ^a   Kusumoto, Fred ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMINOTRANSFERASE; AMIODARONE; AMPHETAMINE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; COCAINE; DECONGESTIVE AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IDRAPARINUX; IRBESARTAN; METHYLXANTHINE; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; QUINIDINE; THROMBIN; THROMBIN INHIBITOR; THYROTROPIN; TRIFLUSAL; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIARRHYTHMIC ACTIVITY; ARTERY CATHETERIZATION; BLEEDING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENTIATION; EMBOLISM; FOOD DRUG INTERACTION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART RATE; HEART RHYTHM; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MEDICAL ASSESSMENT; MINIMALLY INVASIVE SURGERY; PERCUTANEOUS CORONARY INTERVENTION; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; SINUS RHYTHM; SURGICAL TECHNIQUE; THROMBOEMBOLISM;

EID: 13544273529     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-005-0005-7     Document Type: Review

References (47)

1. Feinberg WM, Blackshear JL, Laupacis A, et al.: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473.
2. Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285: 370-2375.
3. Benjamin EJ, Levy D, Vaziri SM, et al.: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844.
4. Vaziri SM, Larson MG, Benjamin EJ, Levy D: Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation 1994, 89:724-730.
5. Mathew JP, Fontes ML, Tudor IC, et al.:investigators of the Ischemia Research and Education Foundation: Multicenter Study of Perioperative Ischemia Research Group. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004, 291: 720-1729.
6. Gage BF, Waterman AD, Shannon W, et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285: 864-2870.
7. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995, 26:1471-1477.
8. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials Arch Intern Med 1994, 154:1449-1457.
9. The Atrial Fibrillation Investigators: The efficacy of aspirin in patients with atrial fibrillation: analysis of pooled data from 3 randomized trials. Arch Intern Med 1997, 157: 237-1240.
10. Stafford RS, Singer DE: National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996, 156: 537-2541.
11. Hylek EM, Chang YC, Skates SJ, et al.: Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000, 160:1612-1617.
12. van Walraven C, Hart RG, Wells GA, et al.: A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003, 163:936-943.
13. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698.
14. Halperin JL: Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor. Exp Rev Cardiovasc Ther 2004, 2:163-174.
15. Eikelboom J, Hankey G: Ximelagatran or warfarin in atrial fibrillation? Lancet 2003, 363:734.
16. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633-638.
17. Perez Gomez F, Lourenzo PI, Companion J, et al.: Platelet aggregation in different antithrombotic regimens. Possible proaggregant effect of low level oral anticoagulation. Rev Port Cardiol 2002, 21:541-551.
18. Perez-Gomez F, Alegria E, Berjon J, et al.: Comparative effects of antiplatelet, anticoagulant or combined therapy in patients with valvular and non-valvular atrial fibrillation. A randomised multi-centre study. J Am Coll Cardiol 2004, 44:1557-1566.
19. Wallentin L, Wilcox RG, Weaver WD, et al.: ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003, 362:789-797.
20. Hohnloser SH, Connolly SJ: Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J Cardiovasc Electrophysiol 2003, 14(9 Suppl):S60-S63.
21. Donnan GA, Dewey HM, Chambers BR: Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 2004, 3: 05-308.
22. Wyse DG, Waldo AL, DiMarco JP, and the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
23. Van Gelder IC, Hagens VE, Bosker HA, et al.: Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
24. Corley SD, Epstein AE, DiMarco JP, et al.: AFFIRM Investigators: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004, 109: 509-1513.
25. Hagens VE, Van Gelder IC, Crijns HJ, Rate Control Versus Electrical Cardioversion of Persistent Atrial Fibrillation (RACE) Study Group: The RACE study in perspective of randomized studies on management of persistent atrial fibrillation. Cardiac Electrophysiol Rev 2003, 7:118-121.
26. Fang MC, Stafford RS, Ruskin JN, Singer DE: National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 2004, 164:55-60.
27. Prasad SM, Maniar HS, Camillo CJ, et al.: The Cox maze III procedure for atrial fibrillation: long-term efficacy in patients undergoing lone versus concomitant procedures. J Thorac Cardiovasc Surg 2003, 126:1822-1828.
28. Sie HT, Buekema WP, Elvan A, et al.: Long-term results of irrigated radiofrequency modified Maze procedure in 200 patients with concomitant cardiac surgery: six years experience. Ann Thorac Surg 2004, 77:512-517.
29. Chiappini B, Martin-Suarez S, LoForte A, et al.: Cox/Maze III operation versus radiofrequency ablation for surgical treatment of atrial fibrillation: a comparative study. Ann Thorac Surg 2004, 77:87-92.
30. Deneke T, Khargi K, Grewe PH, et al.: Left atrial versus biatrial Maze operation using intraoperatively cooled-Tip radiofrequency catheter ablation in patients undergoing open-heart surgery. J Am Coll Cardiol 2002, 39:1644-1650.
31. Williams MR, Stewart JR, Bolling SF, et al.: Surgical treatment of atrial fibrillation using radiofrequency energy. Ann Thorac Surg 2001, 71:1939-1943.
32. Haissaguerre M, Jais P, Shah DC, et al.: Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 1996, 7: 132-1144.
33. Swartz JF, Pellersels G, Silvers J: A catheter based curative approach to atrial fibrillation in humans. Circulation 1994, 90:I-335.
34. Haissaguerre M, Jais P, Shah DC, et al.: Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659-656.
35. Gerstenfeld EP, Guerra P, Sparks PB, et al.: Clinical outcome after catheter ablation for atrial fibrillation J Cardiovasc Electrophysiol 2001, 12:900-908.
36. Marrouche NF, Dresing T, Cole C, et al.: Circular mapping and ablation of the pulmonary vein for treatment of atrial fibrillation: impact of different catheter technologies. J Am Coll Cardiol 2002, 40:464-474.
37. Hsieh MH, Tai CT, Tsai CF, et al.: Clinical outcome of very late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2003, 14:598-601.
38. Saad EB, Rossillo A, Saad CP, et al.: Pulmonary vein stenosis after radiofrequency catheter ablation for atrial fibrillation: functional characterization, evolution, and influence of ablation strategy. Circulation 2003, 108:3102-3107.
39. Pappone C, Rosanio S, Augello G, et al.: Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003, 42: 85-197.
40. Oral H, Scharf C, Chugh A, et al.: Catheter ablation for paroxysmal atrial fibrillation. Segmental ostial ablation versus left atrial ablation. Circulation 2003, 108:2355-2360.
41. Van Gelder IC, Crijns HJ, Tieleman RG, et al.: Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996, 156: 585-2592.
42. Blackshear JL, Odell JA: Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61:755-759.
43. Blackshear JL, Johnson WD, Odell JA, et al.: Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J Am Coll Cardiol 2003, 42:1249-1252.
44. Crystal E, Lamy A, Connolly SJ, et al.: Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. Am Heart J 2003, 145:174-178.
45. Meier B, Palacios I, Windecker S, et al.: Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003, 60:417-422.
46. Sievert H, Lesh MD, Trepels T, et al.: Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002, 105:1887-1889.
47. Omran H, Hardung D, Schmidt H, et al.: Mechanical occlusion of the left atrial appendage. J Cardiovasc Electrophysiol 2003, 14(9 Suppl):S56-S59.